| GO term |
P-value |
Associated genes% |
| Hematopoietic cell lineage |
2.09E-04 |
4.04 |
| IL-17 signaling pathway |
8.26E-06 |
5.32 |
| Intestinal immune network for IgA production |
9.35E-03 |
4.08 |
| Chagas disease (American trypanosomiasis) |
5.22E-07 |
5.88 |
| African trypanosomiasis |
5.42E-03 |
5.41 |
| Malaria |
1.42E-05 |
8.00 |
| Bladder cancer |
2.43E-04 |
7.32 |
| Asthma |
3.82E-03 |
6.45 |
| Allograft rejection |
5.71E-03 |
5.26 |
| Primary immunodeficiency |
5.71E-03 |
5.26 |
| Phosphorylation of CD3 and TCR zeta chains |
1.93E-03 |
9.09 |
| Translocation of ZAP-70 to Immunological synapse |
1.44E-03 |
10.53 |
| Generation of second messenger molecules |
4.59E-03 |
5.88 |
| PD-1 signaling |
2.11E-03 |
8.70 |
| Interleukin-10 signaling |
1.11E-05 |
8.51 |
| FCGR3A-mediated IL10 synthesis |
7.26E-03 |
4.65 |
| Nucleotide-binding Oligomerization Domain (NOD) pathway |
6.62E-03 |
4.88 |
| Allograft Rejection |
1.44E-04 |
4.44 |
| Bladder Cancer |
2.43E-04 |
7.32 |
| IL-3 Signaling Pathway |
9.35E-03 |
4.08 |
| IL1 and megakaryocytes in obesity |
2.50E-03 |
8.00 |
| Photodynamic therapy-induced NF-kB survival signaling |
5.56E-08 |
14.29 |
| Lung fibrosis |
8.64E-04 |
4.76 |
| Hepatitis C and Hepatocellular Carcinoma |
9.72E-03 |
4.00 |
| T-Cell antigen Receptor pathway during Staphylococcus aureus infection |
8.25E-04 |
4.84 |
| Development and heterogeneity of the ILC family |
4.07E-03 |
6.25 |
| Platelet-mediated interactions with vascular and circulating cells |
1.15E-03 |
11.76 |
| LTF danger signal response pathway |
2.71E-05 |
15.00 |
| Cancer immunotherapy by PD-1 blockade |
2.30E-03 |
8.33 |
| Pathogenesis of SARS-CoV-2 Mediated by nsp9/nsp10 Complex |
1.93E-03 |
9.09 |
| COVID-19 AOP |
9.07E-08 |
26.67 |
| Cytokines and Inflammatory Response |
2.91E-03 |
7.41 |
| Type II interferon signaling (IFNG) |
5.42E-03 |
5.41 |
